Figure 5.The effects of the tocilizumab-MIR31HG axis on the AKT pathway in RA-FLS. (A–C) The effects of tocilizumab, MIR31HG and miR-214 on the AKT pathway in RA-FLS. (D, E) The effects of AKT pathway inhibitor, LY294002 on the proliferation and migration of primary RA-FLS. (F) LY294002 mediated rescue of the MIR31HG knockdown-induced expression of inflammatory molecules in RA-FLS. (G–J) LY294002 mediated rescue of the MIR31HG knockdown-induced expression of inflammatory phenotypes in primary macrophages and chondrocytes using an in vitro co-culture system. Data represent the mean ± SEM; **p < 0.01, as determined by the Student’s t-test.
